Novavax (NVAX) EBIT Margin (2010 - 2026)

Novavax's EBIT Margin history runs 17 years deep, the most recent figure standing at 11.06% for Q1 2026.

• In Q1 2026, EBIT Margin fell 8839.0% year-over-year to 11.06%; the TTM figure through Mar 2026 stood at 14.69% (down 4747.0% YoY), while the FY2025 annual figure was 40.3%, up 7679.0% from the prior year.
• EBIT Margin was 11.06% for Q1 2026 at Novavax, down from 9.67% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 77.33% in Q1 2025 to a low of 386.37% in Q1 2023.
• Historically, EBIT Margin has averaged 80.04% across 5 years, with a median of 63.01% in 2023.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin soared 30304 bps in 2022, then plunged 41610 bps in 2023.
• A 5-year view of EBIT Margin shows it stood at 68.24% in 2022, then increased by 8 bps to 63.01% in 2023, then plunged by 136 bps to 148.43% in 2024, then soared by 107 bps to 9.67% in 2025, then tumbled by 214 bps to 11.06% in 2026.
• The last three EBIT Margin figures came in at 11.06% (Q1 2026), 9.67% (Q4 2025), and 252.7% (Q3 2025), per Business Quant data.